Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02277431
Other study ID # 00007145
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date December 2014
Est. completion date October 2015

Study information

Verified date September 2021
Source University of Maryland, Baltimore
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Participants experiencing recurrent gastrointestinal symptoms in this double-blind, randomized, controlled trial will receive either a commercially-available probiotic dietary supplement or placebo. The investigators hypothesize that participants in the probiotic dietary supplement group will experience greater improvement in their gastrointestinal symptoms than participants in the placebo group.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date October 2015
Est. primary completion date September 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Self-reported response of "moderate discomfort" or worse (3 or greater on 1-5 Likert Scale) and "frequent discomfort" or more often (3 or greater on 1-5 Likert scale) from at least 2 of the following gastrointestinal symptoms: gas, indigestion, bloating, abdominal pain, or defecation irregularity as expressed on Likert scale (1=very minor or no discomfort, 2=minor discomfort, 3=moderate discomfort, 4=high discomfort, 5=very high discomfort) over the previous 3 weeks 2. Agree to continue with typical diet and exercise habits during study 3. Agree to use contraception or abstinence throughout study period, unless postmenopausal or surgically sterile (females only) 4. Able to understand and voluntarily consent to the study and understand its nature and purpose including potential risks and side effects Exclusion Criteria: 1. Current and documented diagnosis of Inflammatory Bowel Disease (Crohn's disease or ulcerative colitis), Celiac disease, active peptic ulcer, active diverticulitis, and other active cases of gastrointestinal diseases that, in the investigators' opinions, may affect participant safety. 2. Current and documented diagnosis of any other non-gastrointestinal disease that, in the investigators' opinions, may affect participant safety or confound the evaluation of the study outcomes. Excluded conditions include congestive heart failure, malignancy, uncontrolled diabetes mellitus, uncontrolled autoimmune disease (lupus, rheumatoid arthritis, eczema), eating disorders, and any other active health condition or disease that the investigators feel contradict the intended study population of participants in good health. 3. Daily consumption of another probiotic supplement or new consumption of fermented dairy products (yogurt, kefir, etc.) 4. Usage of systemic steroids during the past 2 months 5. Usage of antipsychotic medications during the past 2 months 6. Usage of prednisone, 6-mercaptopurine, adalimumab, etanercept, infliximab, leflunomide, golimumab, or mycophenolate mofetil during the past 2 months 7. Uncontrolled anxiety or current medication for anxiety disorder 8. Pregnant or breastfeeding females 9. History of alcohol, drug, or medication abuse 10. Known allergies to any substance in the study product 11. Previous major gastrointestinal tract surgery (colon resection, gastric bypass, etc.) 12. Participation in another clinical trial within 30 days of screening

Study Design


Intervention

Dietary Supplement:
Probiotic dietary supplement (Trenev Trio®)
Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am & pm) offering a total daily serving of: Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units [CFU]) Bifidobacterium bifidum Malyoth super strain (40 billion CFU) Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)
placebo


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Maryland, Baltimore

Outcome

Type Measure Description Time frame Safety issue
Other Gastrointestinal Symptom Rating Scale Study end (6 weeks from baseline)
Other Gastrointestinal Quality of Life Index Study end (6 weeks from baseline)
Other Bristol Stool Scale Study end (6 weeks from baseline)
Other Rescue medication usage Study end (6 weeks from baseline)
Other Adequate relief "In the past 7 days, have you had adequate relief of your gastrointestinal discomfort?" Study end (6 weeks from baseline)
Primary Severity of self-reported bloating Likert scale Study end (6 weeks from baseline)
Primary Severity of self-reported gas Likert scale Study end (6 weeks from baseline)
Primary Severity of self-reported indigestion Likert scale Study end (6 weeks from baseline)
Primary Severity of self-reported abdominal pain Likert scale Study end (6 weeks from baseline)
Primary Severity of self-reported defecation irregularity Likert scale Study end (6 weeks from baseline)
Secondary Frequency of self-reported bloating Likert scale Study end (6 weeks from baseline)
Secondary Frequency of self-reported gas Likert scale Study end (6 weeks from baseline)
Secondary Frequency of self-reported indigestion Likert scale Study end (6 weeks from baseline)
Secondary Frequency of self-reported abdominal pain Likert scale Study end (6 weeks from baseline)
Secondary Frequency of self-reported defecation irregularity Likert scale Study end (6 weeks from baseline)
See also
  Status Clinical Trial Phase
Completed NCT04682860 - Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide Phase 4
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Completed NCT02547857 - Transvaginal Pelvic Ultrasound in the ED N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02923245 - POCUS Assessment of Bladder Fullness for Girls Awaiting Radiology-Performed Transabdominal Pelvic Ultrasound N/A
Completed NCT02676232 - DARWeb: an Online Psychosocial Intervention for Children With Recurrent Abdominal Pain and Their Families. N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Recruiting NCT00209807 - Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Phase 4
Terminated NCT01410071 - Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi Dysfunction N/A
Terminated NCT01736280 - Evaluating and Treating Potential Research Participants With Digestive Disorders N/A
Enrolling by invitation NCT04104867 - Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy N/A
Completed NCT03574727 - Abdominal Cutaneous Nerve Entrapment Syndrome
Completed NCT04614649 - Right Iliac Fossa Treatment-Turkey Audit
Completed NCT05438654 - Improvement of Diagnostic Approach Using PoCUS for Right Upper Quadrant Abdominal Pain N/A
Completed NCT06423586 - Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS N/A
Completed NCT03558009 - Epidemiological Analysis for Hereditary Angioedema Disease
Terminated NCT03148288 - Vitamin D Supplementation in IBS N/A
Completed NCT03708874 - Pain Management of Emergency Laparoscopic Cholecystectomy in Patients With Acute Cholecystitis
Withdrawn NCT04408872 - EUS vs EGD in Emergency Room Patients Referred for EGD N/A
Recruiting NCT02594774 - Efficacy of Osteopathic Treatment in Function Abdominal Pain in Children and Adolescents N/A